Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Could AbbVie's New Collaboration Be a Blockbuster?

TheMotleyFool

0 0

Could AbbVie's New Collaboration Be a Blockbuster?

Earlier this month, AbbVie (NYSE: ABBV) announced a deal with biotechnology company Regenxbio (NASDAQ: RGNX) to treat eye disorders using gene therapy. Specifically, the two companies are collaborating to develop and commercialize a gene therapy candidate, RGX-314, which is currently in phase 2 clinical trials.

Let's take a deeper look at this agreement, and the potential revenue it could generate for AbbVie.

Image source: Getty Images.

Source Fool.com

Like: 0

ABBV

Share